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Abstract
Tumor cells often become resistant to DNA damage–based
therapy; however, the underlying mechanisms are not yet
understood. Here, we show that tumor cells exposed to DNA
damage counteract cell death by releasing the antiapoptotic
protein, survivin, from mitochondria. This is independent of
p53, and requires activated checkpoint kinase 2 (Chk2), a
putative tumor suppressor. Molecular or genetic targeting of
Chk2 prevents the release of survivin from mitochondria,
enhances DNA damage–induced tumor cell apoptosis, and
inhibits the growth of resistant in vivo tumors. Therefore,
activated Chk2 circumvents its own tumor-suppressive func-
tions by promoting tumor cell survival. Inhibiting Chk2 in
combination with DNA-damaging agents may provide a
rational approach for treating resistant tumors. (Cancer Res
2006; 66(24): 11576-9)
Introduction
DNA-damaging agents continue to be mainstays of anticancer
therapy (1). Checkpoint kinases, Chk1 and Chk2 (2), are modulators
of the DNA damage response, and relay signals to execute cell cycle
arrest or apoptosis (3). Although Chk2 plays a role in cell cycle
control (3, 4), how this pathway couples to cell survival is
controversial, especially with respect to p53 (5), and is associated
with activation (6–8) or inhibition (9–11) of apoptosis after stress/
DNA damage.
Survivin regulates cell division and inhibits apoptosis in cancer
(12), and has been implicated as a radioresistance factor in tumor
cells (13). This cytoprotective function involves the discharge of a
pool of survivin localized to the mitochondria, which inhibits
apoptosis and promotes in vivo tumor growth (14). Here, we
investigated the signaling circuits initiated by DNA damage in
tumor cells.
Materials and Methods
Cells and cell cultures. Breast adenocarcinoma MCF-7, colon
adenocarcinoma HCT116, or prostate adenocarcinoma PC3 cells were from
the American Type Culture Collection (Manassas, VA). Wild-type (WT),
p53/, or Chk2/ HCT116 cells were kindly provided by Dr. B. Vogelstein
(Johns Hopkins University, Baltimore, MD). HeLa cells were stably
transfected with green fluorescent protein (GFP)-survivin targeted to
mitochondria by the cytochrome c mitochondrial import sequence, as
previously described (14). WT HCT116 cells were stably transfected with a
kinase-dead Asp347 ! Asn Chk2 dominant negative (DN) cDNA (15) under
the control of a tetracycline (tet)-regulated promoter (tet-on, Clontech, Palo
Alto, CA), with conditional induction by 2 Ag/mL of doxycycline.
Modulation of protein expression after DNA damage. Tumor cells
were exposed to ionizing radiation (5–10 Gy) using a 137Cs source
(Gammacell 40), or treated with Adriamycin (0–100 nmol/L; Sigma),
harvested after 2 to 48 hours, and analyzed by Western blotting (14). The
following antibodies to survivin (1:1,000; Novus Biologicals) were used: Chk2
(1:500; Upstate Biotechnology), cytochrome c (1:100; BD Biosciences-
PharMingen), COX-IV (1:500; BD Biosciences-Clontech), p34cdc2 (Cdk1;
Santa Cruz Biotechnology), XIAP (1:1,000; Transduction Laboratories), or
h-actin (1:5,000; Sigma-Aldrich).
Subcellular fractionation. Mitochondrial and cytosolic fractions were
prepared as previously described (14).
Transfections. Gene silencing by small interfering RNA (siRNA) was
carried out with control (VIII) or survivin-derived (S4) double-stranded RNA
oligonucleotide (50 nmol/L), or alternatively, SMART pool siRNA oligonu-
cleotides directed against Chk1 or Chk2 (Dharmacon). A replication-
deficient adenovirus expressing Chk2-DN was constructed using the
pAd-Easy system, and used at a multiplicity of infection of 50.
Fluorescence microscopy. Analysis of mitochondrially targeted
GFP-survivin after ionizing radiation was carried out as previously
described (14).
Apoptosis and colony formation assays. Tumor cells treated with or
without ionizing radiation were harvested after 24 hours, and analyzed for
DNA content by propidium iodide staining, or alternatively, caspase activity
(CaspaTag, Intergen) and plasma membrane integrity by multiparametric
flow cytometry (14). Colony formation in soft agar of transduced WT
HCT116 cells was carried out as described (14).
Xenograft tumor model. All experiments involving animals were
approved by an Institutional Animal Care and Use Committee. Two
HCT116 clones stably transfected with tet-Chk2-DN, exhibiting sensitivity
(no. 102) or resistance (no. 202) to Adriamycin were used. Cells (2.5  106)
were injected into the flanks of 6- to 8-week-old female immunocompro-
mised CB17 severe combined immunodeficiency/beige mice (two tumors/
mouse). Upon the appearance of tumors (100–150 mm3), animals were
randomized into groups and administered doxycycline in the drinking
water (200 Ag/mL in 5% sucrose), with or without Adriamycin (2 mg/kg, i.p.
4 d/wk). Tumor growth was monitored with a caliper according to the
formula 1/2 [length (mm)]  [width (mm)]2, as described in ref. 14. At
the end of the experiment, tumors were excised, and frozen sections from
the various groups were stained with IgG or a FITC-conjugated antibody to
HA, and analyzed by fluorescence microscopy.
Statistical analyses. Data were analyzed using the two-sided unpaired
t test on a GraphPad software package for Windows (Prism 4.0). P = 0.05
was considered statistically significant.
Results
Regulation of survivin expression by DNA damage. Exposure
of MCF-7 cells to ionizing radiation (Fig. 1A), or treatment of
PC3 cells with Adriamycin (Fig. 1B), resulted in time- and
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concentration-dependent increased expression of survivin. In
contrast, DNA damage did not affect the expression of another
related protein, XIAP, or h-actin (Fig. 1A and B). To determine
whether Chk1 or Chk2 (2) were involved in this response, we
first transfected MCF-7 cells with control vector or a kinase-dead
Asp347 ! Asn Chk2-DN mutant. The expression of Chk2-DN
abolished the increase in survivin mediated by ionizing radiation,
whereas a control vector was ineffective (Fig. 2A). We next ablated
Chk2 or Chk1 by siRNA, and analyzed changes in survivin levels
after DNA damage. siRNA targeting Chk1 or Chk2 suppressed the
expression of the two kinases, respectively, whereas Chk1 siRNA
did not affect Chk2, and vice versa (Fig. 2B). Without ionizing
radiation, no significant modulation of survivin was observed after
transfection with the various siRNA (Fig. 2B). In contrast, Chk2
knockdown in MCF-7 cells abolished survivin induction by ionizing
radiation, whereas Chk1 knockdown or a nontargeted siRNA had
no effect (Fig. 2B). Finally, ionizing radiation increased survivin
expression in a time-dependent manner in Chk2+/+ HCT116 cells,
but not in Chk2/ cells (ref. 5; Fig. 2C). Chk2/ cells exhibited
constitutively increased expression of endogenous survivin (Fig. 2C)
and Bcl-2 (Fig. 2D), as compared with parental HCT116 cells. This
may reflect compensatory changes to increase the antiapoptotic
threshold of these cells after loss of Chk2 (see below).
Mechanism of DNA damage–induced survivin expression.
Ionizing radiation did not increase de novo survivin gene
transcription by luciferase promoter analysis, and expression of a
p34cdc2 Asp146 ! Asn kinase-dead mutant that interferes with
mitotic progression also had no effect (Supplemental Fig. S1).
Ionizing radiation modulates survivin independently of gene
expression or the G2-M checkpoint. Therefore, we asked whether
DNA damage induced the redistribution of survivin from existing
intracellular pools, and we focused on the fraction of survivin that
localizes to the mitochondria (14). Without ionizing radiation,
there was no modulation of mitochondrial survivin levels in MCF-7
cells (Fig. 3A). Conversely, ionizing radiation induced nearly
complete discharge of mitochondrial survivin, which coincided
with increased survivin expression in the cytosol, peaking at 12
hours after stimulation (Fig. 3A). Consistent with this time course,
HeLa cells expressing mitochondrially targeted GFP-survivin
exhibited progressive redistribution of the GFP signal from
mitochondria to the cytosol in response to ionizing radiation
(Fig. 3B and C). We then asked whether Chk2 was required for
mitochondrial discharge of survivin after DNA damage. Exposure of
Chk2+/+ HCT116 cells to ionizing radiation resulted in the
discharge of survivin from mitochondria (Fig. 3D). In contrast,
ionizing radiation did not release survivin from the mitochondria
of Chk2/ HCT116 cells (Fig. 3D). Chk2-dependent release of
mitochondrial survivin occurred indistinguishably in HCT116 cells
lacking p53, or deficient in the multidomain proapoptotic protein
Bax (Supplemental Fig. S2), two regulators of outer mitochondrial
membrane permeability.
Role of activated Chk2 in tumor cell survival after DNA
damage. Chk2 knockdown combined with DNA damage increased
caspase activity and loss of plasma membrane integrity in HCT116
cells by 2- to 3-fold (Fig. 4A). This was associated with the
dissipation of mitochondrial membrane potential, and enhanced
release of cytochrome c (Supplemental Fig. S3), independently of
p53 (Supplemental Fig. S4). Survivin knockdown also increased
apoptosis after ionizing radiation (Fig. 4A), consistent with its role
as a Chk2 effector, whereas nontargeted double-stranded RNA
oligonucleotide had no effect (Fig. 4A). We next asked whether
disabling Chk2/survivin cytoprotection affected tumor growth.
First, the expression of Chk2-DN or survivin-DN (16) nearly
completely abolished HCT116 colony formation in soft agar
following ionizing radiation, but not in the absence of ionizing
radiation (Fig. 4B). Second, HCT116 cells conditionally expressing
Chk2-DN after doxycycline induction (Supplemental Fig. S5)
exhibited a 2- to 4-fold increase in apoptosis in response to
Adriamycin (Fig. 4C). Third, we injected tet-Chk2-DN HCT116
clones sensitive (no. 102) or resistant (no. 202) to Adriamycin in
immunocompromised mice to form superficial tumors. Adriamycin
treatment (2 mg/kg) inhibited the growth of sensitive tumors by
50% to 60% (clone no. 102), but had no effect on resistant tumors
(clone no. 202; Fig. 4D). In contrast, conditional expression of
Figure 1. Regulation of survivin expression by DNA damage. A, ionizing
radiation treatment. MCF-7 cells exposed to ionizing radiation were analyzed by
Western blotting. B, Adriamycin treatment. PC3 cells treated with Adriamycin
were analyzed by Western blotting. *, nonspecific.
Figure 2. Requirement of Chk2 for modulation of survivin expression after
ionizing radiation. A, Chk2-DN. Transfected MCF-7 cells with or without ionizing
radiation were analyzed by Western blotting. B, siRNA knockdown. MCF-7
cells transfected with the indicated siRNA were treated with or without ionizing
radiation, and analyzed by Western blotting. *, nonspecific. C, Chk2/ cells.
Top, WT or Chk2/ HCT116 cells were treated with or without ionizing radiation,
and analyzed by Western blotting. Bottom, WT or Chk2/ HCT116 cells were
treated with ionizing radiation, harvested at the indicated time intervals, and
analyzed for changes in survivin levels by Western blotting and quantitative
densitometry. Points, means; bars, SE (n = 3); *, P = 0.01 to 0.044.
D, modulation of Bcl-2 expression. WT or Chk2/ HCT116 cells were analyzed
by Western blotting.
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Figure 3. Mechanism of survivin modulation
by DNA damage. A, mitochondrial release
of survivin. Untreated or ionizing radiation–
treated MCF-7 cells were fractionated in
mitochondrial (left ) or cytosol (right )
extracts, and analyzed by Western blotting.
B, fluorescence analysis. HeLa cells stably
transfected with mitochondrially targeted
GFP-survivin were treated with ionizing
radiation, and analyzed by fluorescence
microscopy. Two independent fields per
condition (top/bottom ). C, quantification of
single cell fluorescence analysis. Individual
cytosolic or mitochondrial areas were
analyzed for changes in fluorescence
intensity before or after ionizing radiation.
Columns, means; bars, SE (n = 46-47).
D, requirement of Chk2 for mitochondrial
release of survivin. Chk2+/+ or Chk2/
HCT116 cells were transduced with
adenovirus encoding mitochondrially targeted
HA-survivin, treated with or without ionizing
radiation, and isolated mitochondrial fractions
were analyzed by Western blotting.
Figure 4. Role of Chk2 cytoprotection in
tumor growth. A, apoptosis. WT HCT116
cells transfected with the indicated siRNA
were treated with or without ionizing radiation,
and analyzed for DEVDase activity
(caspase activity, green channel ) and
propidium iodide staining (red channel ).
The percentage of cells in each quadrant is
indicated. B, colony formation assay. WT
HCT116 cells expressing the indicated
constructs were treated with or without
ionizing radiation, and analyzed for colony
formation in soft agar. Columns, means;
bars, SD (n = 2). C, conditional induction
of apoptosis. HCT116 cells (no. 102)
transfected with doxycycline-Chk2-DN were
treated with or without Adriamycin in the
presence or absence of doxycycline (dox ),
and analyzed for DNA content. The
percentage of cells with hypodiploid DNA
content is indicated. D, tumor growth.
Adriamycin-sensitive (no. 102) or -resistant
(no. 202) HCT116 clones transfected with
doxycycline-Chk2-DN were injected s.c. in
immunocompromised mice. Animals were
administered doxycycline with or without
Adriamycin given 4 d/wk. Points, means of
individual tumor determinations; bars, SE
(no. 102, n = 14; no. 202, n = 6).
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Chk2-DN combined with Adriamycin ablated the growth of
sensitive tumors (clone no. 102), and reduced the expansion of
resistant tumors (clone no. 202) in vivo (Fig. 4D). Histologically,
tumors treated with the combination of Adriamycin and Chk2-DN
exhibited extensive areas of necrosis, as compared with untreated
tumors, or animals receiving Adriamycin or doxycycline alone
(Supplemental Fig. S6). Tumors from doxycycline-treated animals,
but not from untreated mice, stained with an antibody to HA
(Supplemental Fig. S7), confirming the conditional expression of
recombinant Chk2-DN in vivo .
Discussion
In this study, we have shown that activated Chk2 (2) is required
to release antiapoptotic survivin from mitochondria (12) following
DNA damage. Genetic or molecular targeting of Chk2 prevents
survivin release from mitochondria, enhances apoptosis induced by
DNA-damaging agents, inhibits colony formation in soft agar, and
suppresses tumor growth in vivo .
Although considered as a tumor suppressor for its involvement
in cell cycle checkpoints (2), these data suggest that Chk2 may play
a more complex role in tumor cells, including an unexpected
survival signal. The Chk2-regulated discharge of mitochondrial
survivin may enhance cell viability during checkpoint activation or
oncogene expression, and antagonize mitochondria-dependent
apoptosis (14), and mitotic catastrophe (17). How activated Chk2
regulates mitochondrial discharge of survivin remains to be
elucidated. However, this pathway may be selectively exploited in
transformed cells, as opposed to normal tissues. This may explain
why normal tissues exhibit apoptotic defects after Chk2 deletion
(6), and Chk2 mutations/deletions have been associated with low
penetrance cancer risk (2), whereas Chk2 targeting in tumor cells
causes apoptosis (11, 17, 18). Therefore, pharmacologic targeting of
Chk2 (19) may be rationally used in combination with DNA damage
(1) to enhance apoptosis, especially in resistant tumors. Because
Chk2 directly couples to mitochondrial cell death independently of
cell cycle progression, and mitochondrial survivin is selectively
expressed in tumors (14), this strategy may not require the integrity
of the G2 checkpoint, and provide a desirable therapeutic window
with limited toxicity for normal tissues.
Acknowledgments
Received 8/22/2006; revised 10/4/2006; accepted 10/25/2006.
Grant support: NIH grants CA78810, CA90917, and HL54131.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Bert Vogelstein for generously providing HCT116 cells.
Chk2-Mediated Cytoprotection
www.aacrjournals.org 11579 Cancer Res 2006; 66: (24). December 15, 2006
References
1. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a
century of achievements. Nat Rev Cancer 2004;4:737–47.
2. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint
control and cancer. Cancer Cell 2003;3:421–9.
3. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S.
Molecular mechanisms of mammalian DNA repair and
the DNA damage checkpoints. Annu Rev Biochem 2004;
73:39–85.
4. Bartek J, Lukas C, Lukas J. Checking on DNA damage
in S phase. Nat Rev Mol Cell Biol 2004;5:792–804.
5. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The
Chk2 tumor suppressor is not required for p53
responses in human cancer cells. J Biol Chem 2003;
278:20475–9.
6. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice
exhibit radioresistance and defective p53-mediated
transcription. EMBO J 2002;21:5195–205.
7. Stevens C, Smith L, La Thangue NB. Chk2 activates
E2F-1 in response to DNA damage. Nat Cell Biol 2003;5:
401–9.
8. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent
apoptosis after DNA damage is regulated by the check-
point kinase hCds1/Chk2. Nat Cell Biol 2002;4:865–70.
9. Gibson SL, Bindra RS, Glazer PM. Hypoxia-induced
phosphorylation of Chk2 in an ataxia telangiectasia
mutated-dependent manner. Cancer Res 2005;65:
10734–41.
10. Freiberg RA, Hammond EM, Dorie MJ, Welford SM,
Giaccia AJ. DNA damage during reoxygenation elicits a
Chk2-dependent checkpoint response. Mol Cell Biol
2006;26:1598–609.
11. Yu Q, La Rose J, Zhang H, et al. UCN-01 inhibits p53
up-regulation and abrogates gamma-radiation-induced
G(2)-M checkpoint independently of p53 by targeting
both of the checkpoint kinases, Chk2 and Chk1. Cancer
Res 2002;62:5743–8.
12. Altieri DC. Validating survivin as a cancer therapeu-
tic target. Nat Rev Cancer 2003;3:46–54.
13. Chakravarti A, Zhai GG, Zhang M, et al. Survivin
enhances radiation resistance in primary human
glioblastoma cells via caspase-independent mecha-
nisms. Oncogene 2004;23:7494–506.
14. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC.
Mitochondrial survivin inhibits apoptosis and promotes
tumorigenesis. J Clin Invest 2004;114:1117–27.
15. Chehab NH, Malikzay A, Appel M, Halazonetis
TD. Chk2/hCds1 functions as a DNA damage check-
point in G(1) by stabilizing p53. Genes Dev 2000;14:
278–88.
16. O’Connor DS, Wall NR, Porter AC, Altieri DC. A
p34(cdc2) survival checkpoint in cancer. Cancer Cell
2002;2:43–54.
17. Castedo M, Perfettini JL, Roumier T, et al. The
cell cycle checkpoint kinase Chk2 is a negative
regulator of mitotic catastrophe. Oncogene 2004;23:
4353–61.
18. Suganuma M, Kawabe T, Hori H, Funabiki T,
Okamoto T. Sensitization of cancer cells to DNA
damage-induced cell death by specific cell cycle G2
checkpoint abrogation. Cancer Res 1999;59:5887–91.
19. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn
KW. Apoptosis defects and chemotherapy resistance:
molecular interaction maps and networks. Oncogene
2004;23:2934–49.
